|
| Press Releases |
|
 |
|
| Monday, June 3, 2024 |
|
|
エーザイ、創薬イノベーションおよびエコシステム プラットフォーム構築の加速に向けたベンチャー投資事業を強化 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、創薬イノベーションおよびエコシステム プラットフォーム構築の加速に向け、革新的技術やサービスの発掘とそれを有するベンチャー企業の支援、将来的な提携を目的とし、2019 年に開始したベンチャー投資事業を強化し、継続することを決定しましたのでお知らせします。 more info >> |
|
| Tuesday, May 28, 2024 |
|
|
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (lecanemab) for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD (early AD). more info >> |
|
| Thursday, May 23, 2024 |
|
|
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024 |
| Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4. more info >> |
|
| Wednesday, May 22, 2024 |
|
|
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan |
| Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate, "MTX"), in Japan. more info >> |
|
| Wednesday, May 15, 2024 |
|
|
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
| LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
| Monday, May 13, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures |
| Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. more info >> |
|
| Thursday, April 18, 2024 |
|
|
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) |
| Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology. more info >> |
|
| Thursday, November 4, 2021 |
|
|
Eisai and Digital Garage, Inc. Jointly Launch "Onlab Bio Dementia (Open Network Lab BioHealth Dementia Innovation Challenge)" |
| Eisai Co., Ltd. announced today that it launches the "Open Network Lab BioHealth Dementia Innovation Challenge (Onlab Bio Dementia)", a collaborative cultivation program jointly implemented with Digital Garage, Inc., with the aim of contributing to solving issues related to dementia and starts recruiting startups for teams to participate in the program. more info >> |
|
|
Eisai Presents New Data on the Relationship Between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2B Study |
| Eisai Co., Ltd. announced today the presentation of data from the company's extensive Alzheimer's disease (AD) pipeline, including six oral presentations that will provide deeper insights into lecanemab's potential as a treatment for early AD. more info >> |
|
| Monday, November 1, 2021 |
|
|
エーザイとPRISM BioLab共同創製のCBP/β-catenin 阻害剤 E7386 について、臨床における POC（Proof of Concept：創薬概念の検証）を達成 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤 晴夫、以下 エーザイ）と株式会社 PRISM BioLab（本社：神奈川県、代表取締役：竹原 大、以下 PRISM）は、このたび、両社が共同で創製した中分子化合物である CREB-binding protein（CBP）/β-catenin 阻害剤 E7386 について、臨床における POC（Proof of Concept：創薬概念の検証）を達成したことをお知らせします。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
HKTDC launches GreenBiz HK campaign in Bangkok
Mar 18, 2026 19:30: JST
|
|
|
COSCO SHIPPING Ports Announces 2025 Annual Results
Mar 18, 2026 18:36 HKT/SGT
|
|
|
HKTDC launches GreenBiz HK campaign in Bangkok
Mar 18, 2026 18:30 HKT/SGT
|
|
|
中遠海運港口公佈2025年全年業績
Mar 18, 2026 18:26 HKT/SGT
|
|
|
盈立證券勇奪港交所兩項殊榮 港資科技券商實力有目共睹
Mar 18, 2026 17:48 HKT/SGT
|
|
|
盈立证券勇夺港交所两项殊荣 港资科技券商实力有目共睹
Mar 18, 2026 17:48 HKT/SGT
|
|
|
Sunshine Insurance Delivers 2025 Results: Customer Operation System Continues to Innovate
Mar 18, 2026 17:40 HKT/SGT
|
|
|
中远海运港口公布2025年全年业绩
Mar 18, 2026 17:12 HKT/SGT
|
|
|
The 'New Sunshine Strategy' Gains Tangible Results, Sunshine Insurance Group Delivers a High-quality 2025 Performance Report
Mar 18, 2026 16:54 HKT/SGT
|
|
|
AdsDrama Introduces Short Drama Advertising Platform Amid Growth in Digital Content Monetization
Mar 18, 2026 15:30: JST
|
|
|
AdsDrama Introduces Short Drama Advertising Platform Amid Growth in Digital Content Monetization
Mar 18, 2026 14:30 HKT/SGT
|
|
|
三菱重工、新しい経営方針「ITO」の実践による優秀事例を顕彰
Mar 18, 2026 14:00: JST
|
|
|
MHI Commends Outstanding Examples of Implementing its New Management Policy "ITO"
Mar 18, 2026 13:09 JST
|
|
|
Chuangxin Industries Announces 2025 Annual Results
Mar 18, 2026 09:30 HKT/SGT
|
|
|
創新實業公佈2025年全年業績 收入及利潤穩步增長
Mar 18, 2026 09:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
